<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02184520</url>
  </required_header>
  <id_info>
    <org_study_id>PS090007/A10</org_study_id>
    <nct_id>NCT02184520</nct_id>
  </id_info>
  <brief_title>A Prospective Randomized Postmarket Clinical Study of the TRANSITION Stabilization System</brief_title>
  <official_title>A Prospective Randomized Postmarket Clinical Study of the TRANSITION Stabilization System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Globus Medical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Globus Medical Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This postmarket surveillance study is being conducted to evaluate the TRANSITION&#xD;
      Stabilization System as an adjunct to fusion in the treatment of acute or chronic&#xD;
      instabilities or deformities of the thoracic, lumbar and sacral spine. The study will involve&#xD;
      up to 360 subjects at no more than 20 sites, to be treated with the TRANSITION Stabilization&#xD;
      System. The data from this postmarket surveillance study will be provided to FDA in&#xD;
      accordance with the 522 order.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">April 19, 2016</start_date>
  <completion_date type="Actual">May 18, 2017</completion_date>
  <primary_completion_date type="Actual">October 20, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fusion Rates</measure>
    <time_frame>24 months</time_frame>
    <description>The study was terminated prior to primary and secondary endpoint data collection, therefore no study data is reported.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Acute Instabilities Thoracic, Lumbar and Sacral Spine</condition>
  <condition>Chronic Instabilities Thoracic, Lumbar and Sacral Spine</condition>
  <condition>Deformities of the Thoracic, Lumbar and Sacral Spine</condition>
  <arm_group>
    <arm_group_label>TRANSITION</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stabilization System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REVERE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stabilization System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TRANSITION</intervention_name>
    <arm_group_label>TRANSITION</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>REVERE</intervention_name>
    <arm_group_label>REVERE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any of the following acute or chronic instabilities or deformities of the thoracic,&#xD;
             lumbar or sacral spine:&#xD;
&#xD;
          -  degenerative spondylolisthesis with objective evidence of neurologic impairment,&#xD;
&#xD;
          -  kyphosis, or&#xD;
&#xD;
          -  pseudoarthrosis (failed previous fusion)&#xD;
&#xD;
          -  Age 18 or older at the time of consent&#xD;
&#xD;
          -  Able to understand and sign informed consent form&#xD;
&#xD;
          -  Psychosocially, mentally and physically able to comply with protocol&#xD;
&#xD;
          -  Able to meet the proposed follow-up schedule at 6 mo, 12 mo, and 24 mo&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior fusion surgery or another spinal device implanted in the thoracic, lumbar or&#xD;
             sacral spine&#xD;
&#xD;
          -  Requires treatment of more than two vertebral levels&#xD;
&#xD;
          -  Lytic spondylolisthesis at the index level(s)&#xD;
&#xD;
          -  Clinically compromised vertebral bodies at the affected level(s) due to current or&#xD;
             past trauma&#xD;
&#xD;
          -  Sustained pathologic fractures of the spine or hip, including prior fracture or trauma&#xD;
             to vertebral structures at any thoracic, lumbar, or sacral level&#xD;
&#xD;
          -  Morbid obesity defined as a body mass index &gt; 40, or a weight more than 100 lbs over&#xD;
             ideal body weight&#xD;
&#xD;
          -  Pregnant or interested in becoming pregnant within the next 2 years&#xD;
&#xD;
          -  Active systemic or local infection&#xD;
&#xD;
          -  Known allergy to device materials titanium, polycarbonate (PCU), polyethylene&#xD;
             terepthalate (PET), or hydroxyapatite (HA).&#xD;
&#xD;
          -  Taking medications or any drug known to potentially interfere with bone/soft tissue&#xD;
             healing (e.g., steroids, excluding routine NSAIDs)&#xD;
&#xD;
          -  Systemic disease including AIDS, HIV, Hepatitis C&#xD;
&#xD;
          -  Has an active malignancy defined as a history of any invasive malignancy (except&#xD;
             non-melanoma skin cancer), unless he/she has been treated with curative intent and&#xD;
             there has been no clinical signs or symptoms of the malignancy for at least 5 years&#xD;
&#xD;
          -  Neuromuscular disorders such as muscular dystrophy, spinal muscular atrophy,&#xD;
             amyotrophic lateral sclerosis, etc.&#xD;
&#xD;
          -  Participation in an investigational device or drug clinical trials within 30 days of&#xD;
             surgery&#xD;
&#xD;
          -  Acute mental illness or substance abuse&#xD;
&#xD;
          -  Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fort Wayne Orthopaedics</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 3, 2014</study_first_submitted>
  <study_first_submitted_qc>July 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <results_first_submitted>February 18, 2021</results_first_submitted>
  <results_first_submitted_qc>February 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 15, 2021</results_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm, Dissecting</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study was terminated prior to primary and secondary endpoint data collection, therefore no study data is reported.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TRANSITION</title>
          <description>Stabilization System&#xD;
TRANSITION</description>
        </group>
        <group group_id="P2">
          <title>REVERE</title>
          <description>Stabilization System&#xD;
REVERE</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study was terminated prior to primary and secondary endpoint data collection, therefore no study data is reported.</population>
      <group_list>
        <group group_id="B1">
          <title>TRANSITION</title>
          <description>Stabilization System&#xD;
TRANSITION</description>
        </group>
        <group group_id="B2">
          <title>REVERE</title>
          <description>Stabilization System&#xD;
REVERE</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                </category>
                <category>
                  <title>Asian</title>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                </category>
                <category>
                  <title>Black or African American</title>
                </category>
                <category>
                  <title>White</title>
                </category>
                <category>
                  <title>More than one race</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fusion Rates</title>
        <description>The study was terminated prior to primary and secondary endpoint data collection, therefore no study data is reported.</description>
        <time_frame>24 months</time_frame>
        <population>The study was terminated prior to primary and secondary endpoint data collection, therefore no study data is reported.</population>
        <group_list>
          <group group_id="O1">
            <title>TRANSITION</title>
            <description>Stabilization System&#xD;
TRANSITION</description>
          </group>
          <group group_id="O2">
            <title>REVERE</title>
            <description>Stabilization System&#xD;
REVERE</description>
          </group>
        </group_list>
        <measure>
          <title>Fusion Rates</title>
          <description>The study was terminated prior to primary and secondary endpoint data collection, therefore no study data is reported.</description>
          <population>The study was terminated prior to primary and secondary endpoint data collection, therefore no study data is reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <desc>The study was terminated prior to primary and secondary endpoint data collection, therefore no study data is reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>TRANSITION</title>
          <description>Stabilization System</description>
        </group>
        <group group_id="E2">
          <title>REVERE</title>
          <description>Stabilization System</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jacqueline Myer</name_or_title>
      <organization>Globus Medical</organization>
      <phone>610-930-1800</phone>
      <email>jmyer@globusmedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

